S&P 500   4,245.01 (-0.67%)
DOW   33,357.90 (-0.78%)
QQQ   352.08 (-0.60%)
AAPL   169.54 (-1.41%)
MSFT   310.14 (-0.64%)
META   292.47 (-2.17%)
GOOGL   129.16 (+0.46%)
AMZN   125.37 (-0.48%)
TSLA   236.13 (-3.27%)
NVDA   418.00 (-0.26%)
NIO   8.37 (-0.48%)
BABA   85.67 (-0.28%)
AMD   97.00 (+1.08%)
T   14.83 (-1.26%)
F   12.30 (-1.05%)
MU   67.07 (-1.28%)
CGC   0.87 (-5.67%)
GE   110.44 (+0.46%)
DIS   79.39 (-0.82%)
AMC   7.69 (-2.78%)
PFE   32.03 (-1.14%)
PYPL   56.87 (-3.50%)
NFLX   376.94 (-0.61%)
S&P 500   4,245.01 (-0.67%)
DOW   33,357.90 (-0.78%)
QQQ   352.08 (-0.60%)
AAPL   169.54 (-1.41%)
MSFT   310.14 (-0.64%)
META   292.47 (-2.17%)
GOOGL   129.16 (+0.46%)
AMZN   125.37 (-0.48%)
TSLA   236.13 (-3.27%)
NVDA   418.00 (-0.26%)
NIO   8.37 (-0.48%)
BABA   85.67 (-0.28%)
AMD   97.00 (+1.08%)
T   14.83 (-1.26%)
F   12.30 (-1.05%)
MU   67.07 (-1.28%)
CGC   0.87 (-5.67%)
GE   110.44 (+0.46%)
DIS   79.39 (-0.82%)
AMC   7.69 (-2.78%)
PFE   32.03 (-1.14%)
PYPL   56.87 (-3.50%)
NFLX   376.94 (-0.61%)
S&P 500   4,245.01 (-0.67%)
DOW   33,357.90 (-0.78%)
QQQ   352.08 (-0.60%)
AAPL   169.54 (-1.41%)
MSFT   310.14 (-0.64%)
META   292.47 (-2.17%)
GOOGL   129.16 (+0.46%)
AMZN   125.37 (-0.48%)
TSLA   236.13 (-3.27%)
NVDA   418.00 (-0.26%)
NIO   8.37 (-0.48%)
BABA   85.67 (-0.28%)
AMD   97.00 (+1.08%)
T   14.83 (-1.26%)
F   12.30 (-1.05%)
MU   67.07 (-1.28%)
CGC   0.87 (-5.67%)
GE   110.44 (+0.46%)
DIS   79.39 (-0.82%)
AMC   7.69 (-2.78%)
PFE   32.03 (-1.14%)
PYPL   56.87 (-3.50%)
NFLX   376.94 (-0.61%)
S&P 500   4,245.01 (-0.67%)
DOW   33,357.90 (-0.78%)
QQQ   352.08 (-0.60%)
AAPL   169.54 (-1.41%)
MSFT   310.14 (-0.64%)
META   292.47 (-2.17%)
GOOGL   129.16 (+0.46%)
AMZN   125.37 (-0.48%)
TSLA   236.13 (-3.27%)
NVDA   418.00 (-0.26%)
NIO   8.37 (-0.48%)
BABA   85.67 (-0.28%)
AMD   97.00 (+1.08%)
T   14.83 (-1.26%)
F   12.30 (-1.05%)
MU   67.07 (-1.28%)
CGC   0.87 (-5.67%)
GE   110.44 (+0.46%)
DIS   79.39 (-0.82%)
AMC   7.69 (-2.78%)
PFE   32.03 (-1.14%)
PYPL   56.87 (-3.50%)
NFLX   376.94 (-0.61%)
NASDAQ:WVE

Wave Life Sciences (WVE) Stock Forecast, Price & News

$5.31
+0.02 (+0.38%)
(As of 02:03 PM ET)
Compare
Today's Range
$4.92
▼
$5.40
50-Day Range
$3.87
▼
$5.44
52-Week Range
$3.04
▼
$7.12
Volume
169,022 shs
Average Volume
380,555 shs
Market Capitalization
$525.58 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.00
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability

Wave Life Sciences MarketRank™ Forecast

Analyst Rating
Hold
2.43 Rating Score
Upside/​Downside
40.8% Upside
$7.00 Price Target
Short Interest
Bearish
3.46% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.58
Upright™ Environmental Score
News Sentiment
0.22mentions of Wave Life Sciences in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$176,044 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($0.84) to ($1.07) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.19 out of 5 stars

Medical Sector

162nd out of 963 stocks

Pharmaceutical Preparations Industry

58th out of 451 stocks

See Top Rated MarketRank™ Stocks Here

WVE stock logo

About Wave Life Sciences (NASDAQ:WVE) Stock

Wave Life Sciences Ltd., a clinical-stage genetic medicine company, designs, optimizes, and produces novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. It is developing oligonucleotides target ribonucleic acid (RNA) to correct disease-causing mutations, modulate protein activity, restore the production of functional proteins, or reduce the expression of disease-promoting RNAs or proteins. The company also develops WVE-004, a C9orf72 molecule for the treatment of amyotrophic lateral sclerosis and frontotemporal dementia; WVE-003, a mutant huntingtin SNP3 molecule for the treatment of Huntington's disease; WVE-N531, an Exon 53 molecule for the treatment of Duchenne muscular dystrophy; WVE-006, the SERPINA1 molecule for the treatment of Alpha-1 antitrypsin deficiency (AATD); and ATXN3, a discovery stage program for the treatment of spinocerebellar ataxia 3, as well as multiple preclinical programs for CNS disorders, including Alzheimer's and Parkinson's diseases. It has collaboration agreements with Pfizer Inc., Takeda Pharmaceutical Company Limited, and Glaxo Group Limited. The company was incorporated in 2012 and is based in Singapore.

WVE Price History

WVE Stock News Headlines

September 25, 2023 | finance.yahoo.com
Wave Life Sciences to Present at the Chardan 7th Annual Genetic Medicines Conference
September 25, 2023 | americanbankingnews.com
Wave Life Sciences Ltd. (NASDAQ:WVE) Given Consensus Rating of "Hold" by Brokerages
September 27, 2023 | Wall Street Fundamentals (Ad)
The "Plug and Play" Model Putting Online Giants to Shame
While e-commerce has been undergoing a turbulent time, a "simple" model has grown 4X faster than Amazon over the last 3 years. Applying this model to high-margin, recession-resistant businesses has shown to be profitable. But that's just the beginning of explaining the 400+% growth - and potential - of this "diamond in the rough."
September 20, 2023 | americanbankingnews.com
Critical Comparison: Sernova (OTCMKTS:SEOVF) vs. Wave Life Sciences (NASDAQ:WVE)
September 20, 2023 | americanbankingnews.com
Wave Life Sciences (NASDAQ:WVE) and Sernova (OTCMKTS:SEOVF) Head-To-Head Comparison
September 18, 2023 | finance.yahoo.com
We Think Wave Life Sciences (NASDAQ:WVE) Can Easily Afford To Drive Business Growth
September 6, 2023 | finance.yahoo.com
Wave Life Sciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference
September 5, 2023 | finance.yahoo.com
Wave Life Sciences Announces Submission of First Clinical Trial Application for WVE-006, the First-ever RNA Editing Clinical Candidate, and Plans for Upcoming Virtual “R&D Day”
September 27, 2023 | Edge On The Street (Ad)
Is Gold Really Boring?
Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks.
August 23, 2023 | finance.yahoo.com
WAVE Life Sciences Ltd. Sees a 23% Stock Price Surge Over the Past Three Months
August 10, 2023 | finance.yahoo.com
Wave Life Sciences Ltd. (NASDAQ:WVE) Q2 2023 Earnings Call Transcript
August 9, 2023 | markets.businessinsider.com
Truist Financial Sticks to Their Buy Rating for Wave Life Sciences (WVE)
August 8, 2023 | finance.yahoo.com
Analyst Forecasts For Wave Life Sciences Ltd. (NASDAQ:WVE) Are Surging Higher
August 4, 2023 | markets.businessinsider.com
RBC Capital Sticks to Its Hold Rating for Wave Life Sciences (WVE)
August 4, 2023 | finance.yahoo.com
Wave Life Sciences Ltd.'s (NASDAQ:WVE) 42% Price Boost Is Out Of Tune With Revenues
July 27, 2023 | finance.yahoo.com
Wave Life Sciences Second Quarter 2023 Financial Results Scheduled for August 3, 2023
July 6, 2023 | finance.yahoo.com
Wave Life Sciences (NASDAQ:WVE) shareholders have endured a 90% loss from investing in the stock five years ago
July 5, 2023 | msn.com
Analyst Creates Bullish Pitch For WAVE Life Sciences, Says It Is 'Leader To Clinic In RNA Editing'
July 5, 2023 | msn.com
Raymond James Initiates Coverage of Wave Life Sciences (WVE) with Outperform Recommendation
June 26, 2023 | finanznachrichten.de
Wave Life Sciences USA, Inc.: Wave Life Sciences Joins the Russell 2000 and Russell 3000 Indexes
June 26, 2023 | msn.com
Wave Life Sciences gets added to the Russell 2000 and Russell 3000 indexes
June 26, 2023 | finance.yahoo.com
Wave Life Sciences Joins the Russell 2000® and Russell 3000® Indexes
June 23, 2023 | markets.businessinsider.com
Analyst Ratings for WAVE Life Sciences
June 21, 2023 | msn.com
Wave Life Sciences: Less Certainty On Clinical Programs (Rating Downgrade)
June 19, 2023 | finance.yahoo.com
Top Penny Stocks for Q3 2023
June 13, 2023 | entrepreneur.com
3 Pharma Stocks to Buy for a Smart Investment
May 24, 2023 | msn.com
Mizuho Maintains Wave Life Sciences (WVE) Buy Recommendation
See More Headlines
Receive WVE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Wave Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

WVE Company Calendar

Last Earnings
8/03/2023
Today
9/27/2023
Next Earnings (Estimated)
11/09/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:WVE
CUSIP
N/A
CIK
1631574
Web
www.wavelifesciences.com
Phone
(656) 236-3388
Fax
617-949-2901
Employees
250
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$7.00
High Stock Price Forecast
$10.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+31.8%
Consensus Rating
Hold
Rating Score (0-4)
2.43
Research Coverage
7 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($1.36)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-161,820,000.00
Net Margins
-358.93%
Pretax Margin
-357.07%
Return on Equity
N/A
Return on Assets
-63.61%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
1.32
Quick Ratio
1.32

Sales & Book Value

Annual Sales
$3.65 million
Price / Sales
144.00
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.52) per share
Price / Book
-10.21

Miscellaneous

Outstanding Shares
98,980,000
Free Float
68,199,000
Market Cap
$525.58 million
Optionable
Optionable
Beta
-0.94
Beginner's Guide to Pot Stock Investing Cover
Beginner's Guide to Pot Stock Investing

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Dr. Paul B. Bolno M.B.A. (Age 49)
    M.D., MBA, Pres, CEO & Director
    Comp: $1.1M
  • Mr. Kyle B. Moran CFA (Age 52)
    CFO & Principal Accounting Officer
    Comp: $677.87k
  • Dr. Chandra Vargeese Ph.D. (Age 62)
    CTO & Head of Platform Discovery Sciences
    Comp: $710.05k
  • Kate Rausch
    Head of Investor Relations
  • Ms. Linda Rockett J.D.
    Gen. Counsel
  • Dr. Christopher Francis Ph.D. (Age 45)
    Sr. VP of Corp. Devel. & Head of Emerging Areas
  • Mr. Jonathan Rosin
    Chief HR Officer
  • Dr. Sridhar Vaddeboina Ph.D.
    Sr. VP of Chemistry, Manufacturing & Controls
  • Ms. Anne-Marie Li-Kwai-Cheung
    Chief Devel. Officer
  • Dr. Hsiu-Chiung Yang Ph.D.
    Sr. VP of Translational Medicine

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













WVE Stock - Frequently Asked Questions

Should I buy or sell Wave Life Sciences stock right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Wave Life Sciences in the last twelve months. There are currently 4 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" WVE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in WVE, but not buy additional shares or sell existing shares.
View WVE analyst ratings or view top-rated stocks.

What is Wave Life Sciences' stock price forecast for 2023?

7 Wall Street research analysts have issued 12 month price objectives for Wave Life Sciences' shares. Their WVE share price forecasts range from $5.00 to $10.00. On average, they expect the company's share price to reach $7.00 in the next year. This suggests a possible upside of 31.8% from the stock's current price.
View analysts price targets for WVE or view top-rated stocks among Wall Street analysts.

How have WVE shares performed in 2023?

Wave Life Sciences' stock was trading at $7.00 at the start of the year. Since then, WVE shares have decreased by 24.1% and is now trading at $5.31.
View the best growth stocks for 2023 here.

When is Wave Life Sciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023.
View our WVE earnings forecast.

How were Wave Life Sciences' earnings last quarter?

Wave Life Sciences Ltd. (NASDAQ:WVE) announced its earnings results on Thursday, August, 3rd. The company reported ($0.20) earnings per share for the quarter, beating analysts' consensus estimates of ($0.32) by $0.12. The business had revenue of $22.11 million for the quarter, compared to analysts' expectations of $8.08 million.

What ETF holds Wave Life Sciences' stock ?

iShares Neuroscience and Healthcare ETF holds 8,533 shares of WVE stock, representing 0.84% of its portfolio.

What is Paul Bolno, M.D., MBA's approval rating as Wave Life Sciences' CEO?

17 employees have rated Wave Life Sciences Chief Executive Officer Paul Bolno, M.D., MBA on Glassdoor.com. Paul Bolno, M.D., MBA has an approval rating of 92% among the company's employees. This puts Paul Bolno, M.D., MBA in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Wave Life Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Wave Life Sciences investors own include Gilead Sciences (GILD), Exelixis (EXEL), Sangamo Therapeutics (SGMO), Sorrento Therapeutics (SRNE), TherapeuticsMD (TXMD), VBI Vaccines (VBIV), Aduro Biotech (ADRO), Cidara Therapeutics (CDTX), CRISPR Therapeutics (CRSP) and ImmunoGen (IMGN).

What is Wave Life Sciences' stock symbol?

Wave Life Sciences trades on the NASDAQ under the ticker symbol "WVE."

Who are Wave Life Sciences' major shareholders?

Wave Life Sciences' stock is owned by a number of institutional and retail investors. Top institutional shareholders include M28 Capital Management LP (7.12%), 683 Capital Management LLC (6.09%), BlackRock Inc. (4.67%), Kynam Capital Management LP (3.97%), Artal Group S.A. (2.90%) and Geode Capital Management LLC (1.34%). Insiders that own company stock include Chandra Vargeese, Chris Francis, Kyle Moran, Paul Bolno and Ra Capital Management, LP.
View institutional ownership trends.

How do I buy shares of Wave Life Sciences?

Shares of WVE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Wave Life Sciences' stock price today?

One share of WVE stock can currently be purchased for approximately $5.31.

How much money does Wave Life Sciences make?

Wave Life Sciences (NASDAQ:WVE) has a market capitalization of $525.58 million and generates $3.65 million in revenue each year. The company earns $-161,820,000.00 in net income (profit) each year or ($1.36) on an earnings per share basis.

How many employees does Wave Life Sciences have?

The company employs 250 workers across the globe.

How can I contact Wave Life Sciences?

Wave Life Sciences' mailing address is 7 STRAITS VIEW #12-00 MARINA ONE EAST TOWER, SINGAPORE U0, 018936. The official website for the company is www.wavelifesciences.com. The company can be reached via phone at (656) 236-3388, via email at krausch@wavelifesci.com, or via fax at 617-949-2901.

This page (NASDAQ:WVE) was last updated on 9/27/2023 by MarketBeat.com Staff

My Account -